Literature DB >> 27900101

Neoplastic fever in patients with bone and soft tissue sarcoma.

Tomoki Nakamura1, Akihiko Matsumine1, Takao Matsubara1, Kunihiro Asanuma1, Akihiro Sudo1.   

Abstract

The development of fever is a common complication in the clinical course of cancer. If all other potential causes of fever are excluded, the possibility of neoplastic fever should be considered. The aim of the present study was to determine the incidence of neoplastic fever in patients with bone and soft tissue sarcomas. Between January 2009 and December 2014, 195 patients with bone and soft tissue sarcoma (111 men and 84 women; mean age, 55 years) were admitted to the Department of Orthopaedic Surgery of Mie University Graduate School of Medicine (Tsu, Japan). Episodes of fever were observed in 58 patients (30%), of whom 11 (5.5%) had neoplastic fever (mean maximum temperature, 38.9°C). The causes of neoplastic fever were as follows: Primary tumor (n=3), local recurrence (n=1), metastasis (n=5), and local recurrence with metastasis (n=2). Of the 11 patients, 9 were treated with naproxen and 8 exhibited a complete response, with their temperature normalizing to <37.3°C within 24 h. The 2 patients who were not treated with naproxen underwent surgical tumor resection, which resulted in prompt and complete lysis of the fever. In conclusion, neoplastic fever occurred in 5.5% of the 195 patients with bone and soft tissue sarcomas investigated herein. Naproxen may be effective for treating neoplastic fever in patients with bone and soft tissue sarcoma; however, radical tumor treatment may have to be considered to achieve permanent lysis of the fever.

Entities:  

Keywords:  bone sarcoma; naproxen; neoplastic fever; soft-tissue sarcoma

Year:  2016        PMID: 27900101      PMCID: PMC5103890          DOI: 10.3892/mco.2016.1027

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  28 in total

Review 1.  Fever.

Authors:  C A Dinarello; P A Bunn
Journal:  Semin Oncol       Date:  1997-06       Impact factor: 4.929

2.  Cyclo-oxygenase II inhibitors in the treatment of neoplastic fever.

Authors:  Satheesh K Kathula; Ketan Shah; Hari Polenakovik; Jhansi Koduri
Journal:  Support Care Cancer       Date:  2003-03-01       Impact factor: 3.603

3.  Antipyretic effect of naproxen and corticosteroids on neoplastic fever.

Authors:  J C Chang
Journal:  J Pain Symptom Manage       Date:  1988       Impact factor: 3.612

4.  Clinical characteristics of patients with large and deep soft tissue sarcomas.

Authors:  Tomoki Nakamura; Akihiko Matsumine; Takao Matsubara; Kunihiro Asanuma; Astumasa Uchida; Akihiro Sudo
Journal:  Oncol Lett       Date:  2015-05-28       Impact factor: 2.967

5.  Surgical site infection in malignant soft tissue tumors.

Authors:  Takeshi Morii; Kazuo Mochizuki; Takashi Tajima; Shoichi Ichimura; Kazuhiko Satomi
Journal:  J Orthop Sci       Date:  2011-11-26       Impact factor: 1.601

6.  Clinical outcomes of Kyocera Modular Limb Salvage system after resection of bone sarcoma of the distal part of the femur: the Japanese Musculoskeletal Oncology Group study.

Authors:  Tomoki Nakamura; Akihiko Matsumine; Atsumasa Uchida; Akira Kawai; Yoshihiro Nishida; Toshiyuki Kunisada; Nobuhito Araki; Hideshi Sugiura; Masato Tomita; Masahiro Yokouchi; Takafumi Ueda; Akihiro Sudo
Journal:  Int Orthop       Date:  2013-10-26       Impact factor: 3.075

7.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-02-15       Impact factor: 9.079

8.  High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study.

Authors:  G Bacci; S Ferrari; A Longhi; P Picci; M Mercuri; T A Alvegard; G Saeter; D Donati; M Manfrini; S Lari; A Briccoli; C Forni
Journal:  J Chemother       Date:  2002-04       Impact factor: 1.714

9.  Interleukin-6/soluble interleukin-6 receptor signaling attenuates proliferation and invasion, and induces morphological changes of a newly established pleomorphic malignant fibrous histiocytoma cell line.

Authors:  Hirofumi Nakanishi; Kiyoko Yoshioka; Susumu Joyama; Nobuhito Araki; Akira Myoui; Shingo Ishiguro; Takafumi Ueda; Hideki Yoshikawa; Kazuyuki Itoh
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

10.  A Phase II Study of Docetaxel and Epirubicin in Advanced Adult Soft Tissue Sarcomas (STS).

Authors:  Haralabos P Kalofonos; Charalabos Kourousis; Michalis V Karamouzis; Gregoris Iconomou; Ekaterini Tsiata; Fotis Tzorzidis; Panagiotis Megas; Elias Lambiris; Vasilios Georgoulias
Journal:  Sarcoma       Date:  2004
View more
  4 in total

1.  Naproxen for the treatment of neoplastic fever: A PRISMA-compliant systematic review and meta-analysis.

Authors:  Hongliang Zhang; Yuyong Wu; Zhongqiu Lin; Xiaobin Zhong; Taotao Liu; Zhenguang Huang; Yufang Yang
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

2.  Undifferentiated Pleomorphic Sarcoma with Neoplastic Fever: A Retrospective Study.

Authors:  Jiaqiang Wang; Shuping Dong; Jianpo Zhang; Shilei Gao; Zhehuang Li; Po Li; Junhui Yuan; Zhichao Tian
Journal:  Cancer Manag Res       Date:  2021-11-10       Impact factor: 3.989

Review 3.  Aortic Angiosarcoma in Association with Endovascular Aneurysm Repair: Case Report and Review of the Literature.

Authors:  Kaori Takamura; Hiroshi Kobayashi; Brian P Rubin; Shuhei Kondo; Fuyuki Asami; Ryuji Aoyagi; Yoichi Ajioka
Journal:  Am J Case Rep       Date:  2021-06-12

4.  Undifferentiated epithelioid sarcoma presenting as a fever of unknown origin: a case report.

Authors:  Nicholas Sajko; Shannon Murphy; Allen Tran
Journal:  J Med Case Rep       Date:  2019-01-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.